HCA Healthcare, Inc. — Initiating Coverage

Investment Summary

We are initiating coverage of HCA Healthcare (NYSE: HCA) with a Buy rating and a price target of $546.22, representing approximately 33.4% upside from the June 25, 2026 closing price of $409.55. Our price target is derived exclusively from our DCF framework: a probability-weighted average of three scenarios weighted 25% bear, 50% base, and 25% bull. Peer-multiple cross-checks (EV/Revenue, EV/EBITDA, EV/EBIT, and P/E) are presented separately as a market-sentiment sanity check and are not blended into the target price. At 33.4% implied upside, HCA clears our 10% Buy threshold by a wide margin, and even our probability-weighted bear case ($348 per share, 25% weight) implies only 15% downside from current levels, an asymmetric risk-reward profile that supports a conviction Buy.

Our buy thesis rests on three observations: (1) HCA is the best-in-class large-cap hospital operator by virtually every operating metric, with scale, local market density in high-growth Sun Belt geographies, and a management team with a long track record of execution that constitute genuine, durable competitive advantages; (2) despite near-term headwinds from ACA Exchange subsidy expiration and Medicaid supplemental payment program restructuring, our base-case model already conservatively incorporates these dynamics and still produces 37.2% upside to intrinsic value — the headwinds are priced in at current levels and then some; and (3) HCA's aggressive share buyback program ($10.07 billion in FY2025, $10 billion authorized for 2026) is systematically shrinking the share count in a way our static model does not capture, meaning our $546.22 target is conservative relative to what a buyback-adjusted per-share intrinsic value would produce.

We would reassess toward Hold if ACA-related volume headwinds come in materially worse than our bear-case assumptions or if physician labor cost inflation accelerates beyond the high-single-digit growth already embedded in our model. Upward revision to our price target would be warranted if FY2026 EBITDA margin holds above our 20.1% base-case assumption or if HCA discloses material progress on AI-driven efficiency initiatives not currently reflected in our UFCF projections.

---

Company Overview

Business Description

HCA Healthcare is the largest for-profit hospital operator in the United States, with 190 hospitals encompassing approximately 50,436 licensed beds and over 2,400 outpatient facilities as of December 31, 2025. The company operates across 19 U.S. states and England, with a concentrated presence in high-growth Sun Belt markets. HCA generated $75.6 billion in revenue in FY2025, making it one of the largest healthcare companies in the world by revenue.

The company operates across three primary service lines: inpatient hospital services (acute care, behavioral health, rehabilitation), outpatient services (ambulatory surgery centers, endoscopy centers, imaging, urgent care), and physician practice management. Revenue is derived from a mix of government and commercial payers, with commercial and managed care insurance representing the largest and highest-margin category at approximately 48.9% of FY2025 revenue.

Geographic Concentration

The most structurally important fact about HCA's footprint is its concentration in Florida and Texas, which together accounted for approximately 51% of consolidated FY2025 revenue and house 102 of the company's 190 hospitals. This is not incidental — it reflects a deliberate strategy of building dominant local market share in the fastest-growing large states in the country by population and employment. The same concentration that drives above-industry growth also creates idiosyncratic exposure to Florida- and Texas-specific Medicaid policy, regulatory changes, and weather events.

Payer Mix

HCA's payer mix is materially more favorable than the average U.S. hospital system, which is a key driver of its margin premium over peers. FY2025 revenue by payer: commercial and managed care insurers 48.9%, managed Medicare 17.8%, traditional Medicare 14.9%, Medicaid 7.8%, managed Medicaid 4.9%, international 2.5%, and other 3.2%. The near-absence of uncompensated care and the heavy commercial weighting are the primary structural reasons HCA generates EBITDA margins above 20% while the broader hospital industry averages are substantially lower.

Capital Allocation Philosophy

HCA operates with a deliberately leveraged balance sheet and an aggressive share buyback program. The company repurchased $10.07 billion of its own shares in FY2025, $6.04 billion in FY2024, and $3.81 billion in FY2023, with a $10 billion authorization in place as of January 2026. The result is negative shareholders' equity of approximately -$2.5 billion at year-end 2025, total financial debt of $46.5 billion, and diluted EPS growth that consistently outpaces net income growth as the share count shrinks. This is capital discipline in the sense that management is returning cash rather than empire-building, but it also means leverage is structurally elevated by design, leaving less room for error in a downside scenario than a company with a conventional balance sheet would have.

---

Industry & Competitive Landscape

U.S. Hospital Industry Dynamics

The U.S. hospital industry is a regulated, reimbursement-dependent business operating at the intersection of demographic tailwinds and persistent policy risk. Demand is structurally growing: the U.S. population is aging, the 65-and-older cohort uses roughly four times the inpatient services of the under-65 population, and Sun Belt population growth is disproportionately concentrated in HCA's core geographies. These are durable tailwinds that should support above-GDP volume growth for well-positioned operators across the planning horizon.

At the same time, reimbursement is structurally constrained. Medicare rate increases are set annually by CMS and have historically trailed general medical cost inflation by 100 to 200 basis points. Medicaid reimbursement is set at the state level and is subject to budget cycles and federal policy changes, including the restructuring of supplemental payment programs that have historically provided material revenue to large hospital systems. The ongoing direct-to-consumer push by commercial payers and the long-term shift toward value-based care are additional structural headwinds, though the latter is likely a multi-decade transition rather than a near-term earnings risk.

Competitive Position

HCA's competitive position is built on three interlocking advantages that are genuinely difficult for new entrants or smaller operators to replicate:

• Scale and local market density: HCA holds leading or co-leading market share in the majority of the metropolitan areas it serves. Scale matters in hospital markets because it drives more favorable payer contract terms, better physician recruiting leverage, and the ability to amortize fixed technology and administrative costs across a larger revenue base. A small community hospital competing with an HCA-dominated market for managed care contracts is structurally disadvantaged.

• Certificate-of-need regulatory barriers: Many of HCA's core states have certificate-of-need (CON) laws that require regulatory approval for new hospital capacity. While CON laws are not an impenetrable barrier, they meaningfully slow competitive entry and have historically protected established operators from greenfield competition in their core markets.

• Sun Belt demographic positioning: Florida and Texas have above-average population growth driven by domestic in-migration and international immigration, above-average commercial insurance penetration relative to national averages, and relatively favorable state-level regulatory environments for investor-owned hospital systems. HCA's heavy geographic concentration in these states has been a sustained source of volume and pricing advantage versus peers concentrated in slower-growth regions.

Near-Term Headwinds

The 2026 environment introduces several specific headwinds beyond the structural considerations above. The expiration of enhanced Affordable Care Act premium tax credits (eAPTC) is reducing ACA Exchange enrollment and creating both volume and payer mix pressure. Medicaid supplemental payment program restructuring under the FY2026 federal budget act is expected to reduce supplemental revenue in certain states. Third-party physician professional fees continue to grow at high-single-digit rates, outpacing reimbursement rate increases and compressing facility-level margins. These headwinds are real, near-term, and partially quantifiable — they are incorporated into our bear and base case operating assumptions and reflected in the scenario weighting of our price target.

---

Investment Thesis

Bull Case — $911.08 average implied price. The bull case assumes FY2026E revenue of $79.0 billion (+4.5%), gross margin of 43.0%, and a 10-year EBITDA margin trajectory starting at approximately 23.6% before tapering. A terminal growth rate of 3.0% reflects the favorable long-run demographic backdrop of HCA's Sun Belt positioning. The bull scenario requires ACA-related volume headwinds to resolve faster than our base case, physician labor cost pressures to moderate in the back half of 2026, and continued aggressive buyback execution that reduces the share count below our static 230.71 million assumption. Sensitivity range: $690 to $1,200.

Base Case — $562.00 average implied price. The base case assumes FY2026E revenue of $78.6 billion (+4.0%), gross margin of 41.5%, and EBITDA margin of approximately 20.1%, roughly in line with HCA's FY2025 actual of 20.6% with modest dilution from near-term cost pressures. WACC of 7.50% is built bottom-up: 4.49% risk-free rate (10-year U.S. Treasury), 4.18% ERP, 1.13 levered beta. Pre-tax cost of debt of 5.10% weighted across the Senior Note stack, 20.85% effective tax rate. Equity weight 67.0%, debt weight 33.0% at current prices. Net financial debt of $45.5 billion ($46.5 billion gross debt less $1.04 billion cash). Terminal growth rate of 2.5% reflects long-run nominal GDP growth adjusted for the structural hospital volume headwinds from value-based care and payer mix pressure. Sensitivity range: $331 to $956.

Bear Case — $348 average implied price. The bear case assumes FY2026E revenue of $77.9 billion (+3.0%), gross margin of 40.0%, and a materially compressed EBITDA margin of approximately 17.1%, reflecting ACA Exchange volume declines larger than base, continued physician labor cost inflation, and Medicaid supplemental payment program cuts coming in at the high end of guided ranges. Terminal growth rate of 2.0% reflects a more pessimistic view on HCA's long-run volume trajectory. Even in this stressed scenario, the implied equity value of $348 represents only 15% downside from the current price of $409.55, a relatively contained bear case for a business of this operating quality. Sensitivity range: $181 to $632.

Probability-weighting these three scenarios at 25% bear / 50% base / 25% bull produces our $546.22 price target, implying 33.4% upside from the current price. The asymmetry here is notable: the probability-weighted upside of $136.67 per share (+33.4%) is more than double the probability-weighted downside of $61.55 per share (-15.0%). Our model conservatively holds shares outstanding flat at 230.71 million across all 10 projection years — investors who model HCA's $10 billion annual buyback pace explicitly will arrive at a per-share intrinsic value materially above our target, as the shrinking share count amplifies the per-share benefit of compounding owner earnings.

---

Financial Analysis

The table below summarizes key financial metrics across the historical period and our FY2026 base-case projection. HCA's revenue has compounded at approximately 7% annually from FY2022 through FY2025, driven by a combination of volume growth and pricing, with the FY2025 result of $75.6 billion (+7.1%) representing a particularly strong year aided by elevated ACA Exchange volumes and continued post-pandemic utilization normalization. FY2026E reflects a deliberate deceleration in our base case to 4.0%, incorporating the ACA subsidy expiration and Medicaid headwinds discussed in the investment thesis.

Revenue Model

FY2025 actual revenue of $75.6 billion is our projection anchor. Base-case FY2026E of $78.6 billion (+4.0%) reflects same-facility volume growth of approximately 2% and pricing/mix contribution of approximately 2%, consistent with historical normalized trends but below the elevated FY2025 pace. Revenue growth decelerates through the 10-year projection window from 4.0% in FY2026E to 2.5% by FY2034E, as ACA-related volume headwinds normalize and the rate of organic expansion moderates with scale. Bear-case FY2026E of $77.9 billion (+3.0%) and bull-case FY2026E of $79.0 billion (+4.5%) reflect the range of plausible outcomes for the ACA and Medicaid headwind resolution.

Margin Analysis

HCA's gross margin is in transition. The historical gross margin series reflects a vendor reclassification in FY2021 that shifted cost of goods presentation, making direct historical comparisons from pre-2021 to post-2021 uninformative. Our FY2026E base-case gross margin of 41.5% is anchored to the FY2025 actual of 41.5%, with modest downward pressure from physician labor cost inflation and payer mix pressure. EBITDA margin of 20.1% in the base case reflects this same pressure, partially offset by D&A reduction as a percentage of revenue as the capital intensity of HCA's facility base stabilizes.

Capital Expenditure

HCA's CapEx intensity has run at approximately 6.5 to 6.9% of revenue historically, reflecting continued investment in facility upgrades, hospital expansion and renovation, and IT infrastructure. Our base-case FY2026E CapEx of $5.4 billion (6.9% of revenue) assumes maintenance of current investment pace, declining toward approximately 5.9% of revenue by FY2035E as the capital program matures. CapEx is the primary free cash flow swing factor, given the relative stability of the operating income line — modestly higher or lower CapEx intensity materially changes the UFCF generation available to the DCF.

---

Valuation

Price Target Methodology

Our price target of $546.22 is a probability-weighted average of three DCF scenarios, weighted 25% bear, 50% base, and 25% bull. WACC is held constant across all three scenarios at 7.50%, with scenario differentiation driven entirely by the operating assumptions (revenue growth, gross margin, SG&A, CapEx) and the terminal growth rate (bear 2.0%, base 2.5%, bull 3.0%).

The target price reflects our independent estimate of intrinsic value — an assertion about where HCA is mispriced relative to its long-run cash generating capacity, not a claim about where comparable companies trade. Peer-multiple cross-checks are presented below as a market-sentiment reference point but are explicitly not a component of the $546.22 target.

DCF Scenario Summary

DCF Methodology

Our primary valuation methodology is a 10-year unlevered free cash flow (UFCF) model with a Gordon Growth Model terminal value. UFCF is defined as NOPAT (EBIT × (1 − tax rate)) plus D&A, less capital expenditures and changes in net working capital. The model is capital-structure-neutral at the cash-flow stage; the capital structure enters through WACC at the discount-rate stage and through net financial debt at the equity bridge. Operating lease liabilities are treated as operating costs within EBIT rather than financial debt, consistent with UFCF convention.

Our 10-year DCF holds diluted shares outstanding constant at 230.71 million. Given HCA's stated $10 billion annual buyback pace, this is a deliberately conservative assumption — the company is actively retiring shares at a rate that would materially reduce the denominator of our per-share implied value over the projection window. Treating shares as static understates per-share intrinsic value to the extent buybacks continue at historical rates.

WACC Derivation

DCF Detail

Terminal value as a percentage of enterprise value (63.1% bear, 63.2% base) is meaningfully higher than in capital-light franchised businesses, reflecting HCA's more capital-intensive, mature business where near-term free cash flow is partially offset by elevated CapEx. The higher terminal value weighting increases sensitivity to WACC and TGR assumptions, which is the primary driver of the wide sensitivity ranges presented below.

Sensitivity Analysis: Base Case

The table below shows base-case DCF-derived implied share prices across a WACC and terminal growth rate grid. The highlighted cell at 7.50% WACC / 2.50% TGR is the base-case central estimate of $591.18 before the probability-weighted averaging that produces our $546.22 target.

Highlighted cell = base-case central estimate ($591.18 pre-probability-weighting). Wide range reflects high terminal value weighting and WACC/TGR proximity at lower WACC bounds.

Comparable Company Analysis

We present a five-peer comparable company analysis using NTM multiples. No pure-play acute-care hospital operator of comparable scale exists, so the peer set necessarily includes diversified facility operators whose operating models differ from HCA's in meaningful ways. HCA is a category-of-one at its scale, which is part of why the peer median multiples below systematically understate what a scale-premium-adjusted valuation would assign to HCA specifically.

¹ CYH P/E excluded from median calculation due to near-zero EPS reflecting distressed earnings rather than a valuation reference. ² P/E median calculated excluding CYH: median of THC (11.0x), UHS (6.1x), EHC (16.6x), DVA (9.8x) = 10.4x.

Multiples Cross-Check (Not a Target Price Input)

All four peer-median multiples imply share prices below the current price, ranging from $191 (EV/EBITDA) to $353 (P/E). This reflects that our peer set trades at multiples substantially below where HCA has historically commanded a premium. The EV/EBITDA cross-check in particular (peer median 5.65x implying $191) is distorted by the inclusion of Tenet (4.0x) and CYH (4.8x), both of which carry significant debt burdens and credit concerns unrelated to HCA's situation. At 8.0 to 9.7x EV/EBITDA, a multiple range more consistent with best-in-class operator premiums, the implied share price would range from approximately $317 to $494.

---

Key Risks

Downside Risks

• ACA Exchange and Medicaid Headwinds (HIGH): The expiration of enhanced ACA premium tax credits and restructuring of Medicaid supplemental payment programs represent the single most significant near-term earnings risk. Management has guided to a combined impact in 2026; the bear case assumes these headwinds come in at the high end of guidance, compressing both volume and payer mix.

• Physician Labor Cost Inflation: Third-party physician professional fees are growing at high-single-digit rates, driven by persistent labor shortages in specialty clinical labor. This cost category does not respond to traditional labor market normalization at the same pace as contract nursing labor, and represents a multi-year margin headwind if not offset by reimbursement rate increases.

• Florida and Texas Geographic Concentration: 51% of consolidated revenue is concentrated in two states. State-specific Medicaid policy changes, regulatory shifts, or weather events (hurricanes in Florida particularly) create idiosyncratic risk that a more geographically diversified operator would not face.

• Leverage and Negative Shareholders' Equity: $45.5 billion in net financial debt and negative equity create meaningful downside amplification in a stressed scenario. A 10% decline in enterprise value translates to a proportionally larger decline in equity value due to the fixed-debt overhang.

• Value-Based Care as a Long-Term Structural Headwind: As more physician payments tie to outcomes and reduced readmissions, inpatient volume growth is structurally pressured over the long run. This is the primary reason our terminal growth rates (2.0 to 3.0%) are below nominal GDP growth.

• Reimbursement Rate Risk: Annual Medicare rate updates have historically trailed medical cost inflation. Any year where operating cost growth exceeds reimbursement rate increases without commercial contract offsets compresses facility-level margins in a business that is already operating near its structural EBITDA margin ceiling.

Upside Risks

• ACA Headwind Resolution Faster Than Expected: If ACA Exchange enrollment declines prove more modest than guided, or if Medicaid supplemental program restructuring is phased in more slowly, FY2026 revenue and margin could track closer to our bull-case assumptions. This is the single most actionable upside catalyst for the near-term investment case.

• Share Buyback Accretion Exceeds Static Assumption: Our model holds diluted shares at 230.71 million throughout the 10-year projection window. At HCA's historical $8 to $10 billion annual pace, the actual share count at year-end 2035 would be materially lower, driving per-share intrinsic value above our $546.22 target without any change in operating assumptions.

• Sun Belt Population Growth Secular Tailwind: Texas and Florida continue to attract domestic in-migration and international immigration at above-national rates. If this demographic tailwind sustains above-industry volume growth for HCA's core geographies, the base-case revenue growth trajectory could be too conservative in the outer projection years.

• Margin Recovery From Physician Labor Normalization: If specialist labor market conditions ease in 2027 and beyond, the high-single-digit growth in professional fees could decelerate, restoring facility-level margins toward the FY2025 baseline.

• Technology Optionality: HCA is investing in AI-driven clinical efficiency and administrative automation tools. None of these investments are attributed standalone value in our UFCF model. Material efficiency gains from technology deployment would represent incremental upside not captured in our projection.

---

Recommendation

We initiate coverage of HCA Healthcare (NYSE: HCA) with a Buy rating and a price target of $546.22, derived from a probability-weighted average of our three DCF scenarios (25% bear / 50% base / 25% bull). At the current price of $409.55, the implied upside of 33.4% clears our 10% Buy threshold by a wide margin, and the risk-reward is asymmetric in the investor's favor: probability-weighted upside of $136.67 per share versus probability-weighted downside of $61.55 per share.

The investment case is straightforward. HCA is the dominant hospital operator in the United States, with best-in-class margins, a management team with a decades-long track record of execution, and a geographic concentration in the two fastest-growing large states in the country. These are not temporary advantages. The scale premium that allows HCA to negotiate better managed care contracts, recruit more selectively, and amortize fixed costs across a larger revenue base compounds over time, not against it. The Sun Belt demographic tailwind, driven by domestic in-migration and continued population growth in Florida and Texas, directly supports the volume trajectory embedded in our base case.

Near-term headwinds from ACA Exchange subsidy expiration and Medicaid supplemental program restructuring are real, and they are already conservatively incorporated into our base-case and bear-case operating assumptions. The current share price of $409.55 reflects a market that has priced these headwinds in — and then some. Our base case alone, without any bull-case weighting, implies $562 per share, 37.2% above current levels. The bear case implies $348, only 15% below current levels, even under a scenario where multiple headwinds materialize simultaneously. That asymmetry is the core of the Buy thesis.

HCA's aggressive capital return program is an additional source of value not fully reflected in our static-share-count model. At $10 billion in annual buybacks against a current market cap of approximately $94.5 billion, the company is retiring more than 10% of its own equity annually. Every dollar of that buyback at current prices adds to per-share intrinsic value in a way that a DCF holding shares flat at 230.71 million understates. Investors entering here at $409.55 are buying into a machine that is simultaneously compounding operating earnings and compressing the share count against which those earnings are divided.

New investors should initiate a position at current levels. Current holders should add on weakness toward the bear-case sensitivity range, where the margin of safety widens further.